Improzo

Improzo: The Execution Layer for Life Sciences

Pharma has already bought the systems. Most life sciences companies run Veeva, Salesforce, Snowflake, IQVIA data, and a stack of analytics tools. Yet the gap between insight and action persists. Field insights stay trapped in notes, medical and market signals are summarized by hand, and launch and leadership decisions move too slowly. Improzo closes that gap. Improzo's iZOTM installs domain-trained AI agents and pre-built accelerators directly inside the technology customers already own, including Veeva, Salesforce, IQVIA, Snowflake, Databricks, and Tableau. There is no new system of record, no data migration, and no rip-and-replace. Governance and compliance are built in, not bolted on. The timing is new. For the first time, AI agents can operate inside these enterprise systems directly, and pharma buyers are moving away from long, costly platform contracts toward outcomes delivered quickly. Incumbent analytics firms built on services revenue are poorly positioned to make this shift. Improzo's model compounds. Every accelerator draws on a shared library of reusable agents, domain intelligence, and guardrails. The first deployment creates the foundation, the second goes live faster, and the third costs less. Customers start with one focused business problem, see value in weeks rather than months, and expand across commercial, medical, and enterprise functions. Improzo's iZOTM is already live in production at leading biopharma companies. Improzo was selected for the Snowflake Startup Accelerator, Winter 2026 cohort, and recognized in the AI Impact of the Year category at the 2026 Digital Engineering Awards. Improzo's founding team includes former leaders from IQVIA, ZS, Takeda, and Otsuka who have built, scaled, and exited businesses in life sciences analytics and technology. They are not learning this market from the outside. Many of them were the customer.

The result is AI that makes the pharma stack execute.